Sign up USA
Proactive Investors - Run By Investors For Investors

Bristol-Myers Squibb to get keys to Padlock

Bristol-Myers Squibb Company is to snap up Padlock Therapeutics
Bristol-Myers Squibb to get keys to Padlock
Bristol-Myers Squibb to buy Padlock

Bristol-Myers Squibb Company (NYSE:BMY) is to snap up Padlock Therapeutics, it was announced on Wednesday.

The companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Padlock, a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases.

The acquisition will give Bristol-Myers Squibb full rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program focused on the development of potentially transformational treatment approaches for patients with rheumatoid arthritis (RA).

Padlock’s PAD discovery programme may have additional utility in treating systemic lupus erythematosus (SLE) and other autoimmune diseases.

Bristol-Myers shares closed down 0.73% at $62.34.



Register here to be notified of future BMY Company articles
View full BMY profile

Bristol Myers Squibb Timeline

Related Articles

shutterstock_184785974.jpg
April 28 2016
Last year's acquisition of Kinesis Pharma meant that it could now offer a one-stop shop for its pharmaceuticals clients and expand its client base.
Harley Street London street sign
Fri
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.
FatCity.jpg
January 13 2016
If everyone could be as active as the York-based outfit there would not be such a pressing demand for its products.
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC